Want to see AMGN full AI Analyst Report?
AMGN Stock Chart & Stats
$442.24
$5.07(1.35%)
At close: 4:00 PM EDT
$442.24
$5.07(1.35%)
Day’s Range― - ―
52-Week Range$288.00 - $447.03
Previous CloseN/A
Volume233.75K
Average Volume (3M)3.05M
Market Cap
$229.74B
Enterprise Value$240.31B
Total Cash (Recent Filing)$13.99B
Total Debt (Recent Filing)$57.30B
Price to Earnings (P/E)27.1
Beta0.33
Next Earnings
Nov 03, 2026EPS Estimate
5.78Next Dividend Ex-DateN/A
Dividend Yield2.26%
Share Statistics
EPS (TTM)16.22
Shares Outstanding540,632,000
10 Day Avg. Volume2,662,710
30 Day Avg. Volume3,050,063
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)20.34
Price to Sales (P/S)4.79
P/FCF Ratio21.74
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue6.30
Enterprise Value/Gross Profit8.68
Enterprise Value/Ebitda13.64
Forecast
1Y Price Target
$404.17Price Target Upside-8.61% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering27
EPS Forecast (FY)23.05
Revenue Forecast (FY)$38.99B
Bulls Say, Bears Say
Bulls Say
Diversified Product GrowthGrowth is spread across multiple products and therapeutic areas rather than concentrated in one franchise. That breadth supports portfolio resilience, creates more opportunities for cross-market expansion, and helps offset pressure from individual products losing exclusivity.
Strong Profitability And Cash GenerationHigh margins and substantial free cash flow demonstrate strong earnings quality and the ability to fund research, manufacturing capacity, dividends, and business development internally. This cash generation also provides an important buffer against product-cycle volatility.
Pipeline And Capacity InvestmentAdvancing late-stage programs while expanding manufacturing capacity strengthens Amgen’s potential product pipeline and commercial readiness. If development milestones are achieved, these investments can support future revenue replacement and extend the company’s growth runway.
Bears Say
High Balance-sheet LeverageAmgen’s sizable debt burden reduces financial flexibility and makes the company more sensitive to refinancing costs or an earnings downturn. Although leverage has improved from prior years, debt remains high relative to equity and could constrain capital allocation.
Biosimilar Pressure On Prolia And XGEVAThe decline shows that biosimilar competition can materially erode revenue from established products. Continued pressure on this franchise could offset growth elsewhere, reduce portfolio profitability, and increase the need for successful launches and indications.
Pipeline Execution UncertaintyPipeline setbacks and unresolved clinical readouts create uncertainty around future product launches and revenue replacement. Failed or delayed programs can reduce the return on R&D spending and leave Amgen more dependent on existing brands and acquisitions.
Amgen News
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $288.00 and its highest was $447.03 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is $229.74B.
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Nov 03, 2026 which is in 13 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Aug 04, 2026. The company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.617 by $0.673.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Overvalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.52 which represents an annual dividend yield of 2.26%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 5.78.
How many shares outstanding does Amgen have?
Amgen has 540,632,000 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $6.29 in its last earnings report, beating expectations of $5.617. Following the earnings report the stock price went up 4.567%.
Which hedge fund is a major shareholder of Amgen?
Currently, no hedge funds are holding shares in AMGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$404.17 (-8.61% Downside)
$404.17 (-8.61% Downside)
Blogger Sentiment
Bullish
AMGN Sentiment 74%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $825.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.72%
12-Months-Change
Fundamentals
Return on Equity
89.32%
Trailing 12-Months
Asset Growth
8.81%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Amgen
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
AMGN Company Deck
AMGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reported broad-based commercial strength (10% revenue growth, multiple products with double-digit increases, raised full-year guidance), robust margins (48% non-GAAP operating margin) and strong cash generation, while also flagging expected near-term expense increases, higher cost-of-sales pressure from mix and profit-share, a material decline in the Prolia/XGEVA franchise (–33%), and some pipeline uncertainty/readouts pending. On balance the positive commercial execution, raised guidance and pipeline momentum outweigh the noted headwinds.View all AMGN earnings summariesAMGN Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
AMGN Stock 12 Month Forecast
Average Price Target
$404.17
▼(-8.61% Downside)
Technical Analysis
Ownership Overview
0.21% Insiders
24.25% Mutual Funds
1.78% Other Institutional Investors
41.89% Public Companies and Individual Investors